A Phase 1/2 Trial of Low-Dose Continuous Azacitidine in Combination with Lenalidomide and Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma

Autor:	Robert M. Dean, Hillard M. Lazarus, Christy J. Samaras, Frederic J. Reu, Hien Liu, Janice Reed, Nathaniel Rosko, Eshan Malek, Dale Grabowski, Kimberly Hamilton, Jason Valent, Yogen Saunthararajah, Sherry Fada, Reda Z. Mahfouz, Wei Wei, Jack Khouri, Mary Ann Karam, Beth Faiman, Matt Kalaycio, Yap Chew
Rok vydání:	2019
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Azacitidine Low dose Hematology medicine.disease Internal medicine Relapsed refractory medicine business Dexamethasone Multiple myeloma medicine.drug Lenalidomide
Zdroj:	Clinical Lymphoma Myeloma and Leukemia. 19:e262-e263
ISSN:	2152-2650
DOI:	10.1016/j.clml.2019.09.434
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d88cf534d35312f22d518ebbc3a2bc29 https://doi.org/10.1016/j.clml.2019.09.434 Zobrazit plný text záznamu Full Text from ScienceDirect